Oral estramustine and oral etoposide for hormone-refractory prostate cancer

By Dimopoulos M.A.   Panopoulos C.   Bamia C.   Deliveliotis C.   Alivizatos G.   Pantazopoulos D.   Constantinidis C.   Kostakopoulos A.   Kastriotis I.   Zervas A.   Aravantinos G.   Dimopoulos C.  

Urology, Vol. 50, Iss. 5, 1997-11 ,pp. : 754-758

Elsevier

Access to resources Recommend Favorite

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

By Haas N.   Roth B.   Garay C.   Yeslow G.   Entmacher M.   Weinstein A.   Rogatko A.   Babb J.   Minnitti C.   Flinker D.   Gillon T.   Hudes G.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 59-64

Elsevier

Access to resources Recommend Favorite

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

By Clark P.E.   Peereboom D.M.   Dreicer R.   Levin H.S.   Clark S.B.   Klein E.A.  

Urology, Vol. 57, Iss. 2, 2001-02 ,pp. : 281-285

Elsevier

Access to resources Recommend Favorite

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

By Samelis G.F.   Skarlos D.   Bafaloukos D.   Kosmidis P.   Anagnostopoulos A.   Aravantinos G.   Dimopoulos M.A.  

Urology, Vol. 61, Iss. 6, 2003-06 ,pp. : 1211-1215

Elsevier

Access to resources Recommend Favorite

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer - a controlled study

By Smith D.C.   Redman B.G.   Flaherty L.E.   LI L.   Strawderman M.   Pienta K.J.  

Urology, Vol. 52, Iss. 2, 1998-08 ,pp. : 257-260

Elsevier

Access to resources Recommend Favorite